EA201200098A1 - Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия - Google Patents

Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия

Info

Publication number
EA201200098A1
EA201200098A1 EA201200098A EA201200098A EA201200098A1 EA 201200098 A1 EA201200098 A1 EA 201200098A1 EA 201200098 A EA201200098 A EA 201200098A EA 201200098 A EA201200098 A EA 201200098A EA 201200098 A1 EA201200098 A1 EA 201200098A1
Authority
EA
Eurasian Patent Office
Prior art keywords
malarium
treatment
compositions intended
parasitic diseases
condensed imidazoles
Prior art date
Application number
EA201200098A
Other languages
English (en)
Other versions
EA019655B1 (ru
Inventor
Арнаб К. Чаттерджи
Адваит Нагл
Тао Ву
Дейвид Талли
Келли Л. Куэн
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200098(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA201200098A1 publication Critical patent/EA201200098A1/ru
Publication of EA019655B1 publication Critical patent/EA019655B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны класс соединений, фармацевтические композиции, содержащие такие соединения, и способы применения таких соединений для лечения или предупреждения малярии.
EA201200098A 2009-07-09 2010-07-09 Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия EA019655B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22443309P 2009-07-09 2009-07-09
PCT/US2010/041626 WO2011006143A2 (en) 2009-07-09 2010-07-09 Compounds and compositions for the treatment of parasitic diseases

Publications (2)

Publication Number Publication Date
EA201200098A1 true EA201200098A1 (ru) 2012-07-30
EA019655B1 EA019655B1 (ru) 2014-05-30

Family

ID=42727573

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200098A EA019655B1 (ru) 2009-07-09 2010-07-09 Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия

Country Status (38)

Country Link
US (3) US8557801B2 (ru)
EP (2) EP2737927B1 (ru)
JP (1) JP5432376B2 (ru)
KR (1) KR101378666B1 (ru)
CN (1) CN102471341B (ru)
AR (1) AR077463A1 (ru)
AU (1) AU2010271247B2 (ru)
BR (1) BR112012000413B1 (ru)
CA (1) CA2767664C (ru)
CL (1) CL2012000042A1 (ru)
CO (1) CO6491060A2 (ru)
CR (1) CR20120008A (ru)
CU (1) CU24155B1 (ru)
DK (1) DK2451814T3 (ru)
EA (1) EA019655B1 (ru)
EC (1) ECSP12011585A (ru)
ES (2) ES2477940T3 (ru)
GT (1) GT201200004A (ru)
HK (1) HK1164304A1 (ru)
HN (1) HN2012000023A (ru)
HR (1) HRP20140641T1 (ru)
IL (1) IL217384A (ru)
JO (1) JO3156B1 (ru)
MA (1) MA33419B1 (ru)
MX (1) MX2012000389A (ru)
MY (1) MY157238A (ru)
NZ (1) NZ597275A (ru)
PE (1) PE20130399A1 (ru)
PL (1) PL2451814T3 (ru)
PT (1) PT2451814E (ru)
SG (1) SG176938A1 (ru)
SI (1) SI2451814T1 (ru)
SM (1) SMT201400096B (ru)
TN (1) TN2011000647A1 (ru)
TW (1) TWI421252B (ru)
UA (1) UA103930C2 (ru)
UY (1) UY32776A (ru)
WO (1) WO2011006143A2 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2884767A1 (en) 2012-11-14 2014-05-22 Stephan Bachmann Imidazopyridine derivatives
ME03042B (me) * 2012-11-19 2018-10-20 Novartis Ag Jedinjenja i kompozicije za tretman parazitskih oboljenja
US20150291598A1 (en) * 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN103126782B (zh) * 2013-02-26 2016-06-29 内蒙古农牧业科学院 一种寄生病的治疗方法
CN106029666B (zh) * 2013-12-19 2018-05-18 诺华股份有限公司 作为原生动物蛋白酶体抑制剂用于治疗寄生虫疾病例如利什曼病的[1,2,4]三唑并[1,5-a]嘧啶衍生物
US10526325B2 (en) 2015-07-31 2020-01-07 Merck Patent Gmbh Bicyclic heterocyclic derivatives
BR112019003158B1 (pt) * 2016-08-15 2022-10-25 Bayer Cropscience Aktiengesellschaft Derivados de heterociclo bicíclico condensado, seu uso, formulação agroquímica, e método para controlar pragas animais
WO2018198021A1 (en) * 2017-04-24 2018-11-01 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
LT3652178T (lt) 2017-07-14 2024-04-10 F. Hoffmann-La Roche Ag Bicikliniai ketoniniai junginiai ir jų naudojimo būdai
JP2020536853A (ja) * 2017-10-04 2020-12-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 転写因子ｓａｌｌ４の小分子阻害およびその使用
WO2022049548A1 (en) 2020-09-04 2022-03-10 Novartis Ag Kaf156 combinations and methods for the treatment of malaria
WO2023168107A2 (en) * 2022-03-04 2023-09-07 University Of Central Florida Research Foundation, Inc. Compounds and compositions for anitmalarial therapeutic and prophylactic use
CN114569711B (zh) * 2022-03-24 2024-04-19 安徽医科大学 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用
WO2024006970A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
RU2263111C2 (ru) 1998-06-12 2005-10-27 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас Имидазольные производные
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
ES2328564T3 (es) * 1998-12-31 2009-11-16 Ipsen Pharma Inhibidores de la prenil transferasa.
CZ20021550A3 (cs) 1999-11-09 2003-02-12 Societe De Conseils De Recherches Et D'application Produkt zahrnující inhibitor transdukce signálů heterotrimerického G proteinu kombinovaný s jiným protirakovinným činidlem pro terapeutické použití v léčbě rakoviny
FR2803525B1 (fr) 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
ATE360620T1 (de) 2000-08-01 2007-05-15 Sod Conseils Rech Applic Imidazolderivate
WO2002053558A1 (en) * 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7307164B2 (en) 2002-03-25 2007-12-11 Merck & Co., Inc. β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004028541A2 (en) 2002-09-27 2004-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Composition for the treatment of nasopharyngeal carcinoma and use thereof
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
EP1583534A4 (en) * 2002-12-20 2007-08-29 Merck & Co Inc 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
CA2517427C (en) * 2003-03-06 2012-07-24 Merck & Co., Inc. Antiprotozoal imidazopyridine compounds
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
ATE447574T1 (de) 2003-05-14 2009-11-15 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
BRPI0614732A2 (pt) 2005-08-11 2011-04-12 Hoffmann La Roche composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
CN101495113A (zh) 2006-04-21 2009-07-29 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
WO2008006085A2 (en) 2006-07-07 2008-01-10 University Of Washington Compositions and methods for predicting inhibitors of protein targets
TW200808056A (en) * 2006-07-26 2008-02-01 Compal Communications Inc Rear projection display system
EA200900983A1 (ru) 2007-01-26 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов киназы
US20080242862A1 (en) * 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
CN101357922B (zh) 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009155388A1 (en) 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
CR20120008A (es) 2012-03-12
CL2012000042A1 (es) 2012-12-21
ES2477940T3 (es) 2014-07-18
GT201200004A (es) 2014-03-27
TW201105675A (en) 2011-02-16
CU24155B1 (es) 2016-03-31
US9963454B2 (en) 2018-05-08
AU2010271247A1 (en) 2012-01-19
NZ597275A (en) 2013-05-31
JP5432376B2 (ja) 2014-03-05
IL217384A (en) 2015-07-30
EP2451814B1 (en) 2014-04-09
EA019655B1 (ru) 2014-05-30
UA103930C2 (ru) 2013-12-10
US20110059934A1 (en) 2011-03-10
KR20120047939A (ko) 2012-05-14
CN102471341B (zh) 2014-07-02
KR101378666B1 (ko) 2014-03-26
MA33419B1 (fr) 2012-07-03
HRP20140641T1 (hr) 2014-09-26
IL217384A0 (en) 2012-02-29
CO6491060A2 (es) 2012-07-31
PL2451814T3 (pl) 2014-09-30
AR077463A1 (es) 2011-08-31
EP2451814A2 (en) 2012-05-16
SMT201400096B (it) 2014-09-08
TN2011000647A1 (en) 2013-05-24
SG176938A1 (en) 2012-01-30
HN2012000023A (es) 2014-08-18
EP2737927B1 (en) 2016-03-30
ECSP12011585A (es) 2012-02-29
CA2767664C (en) 2013-12-10
PE20130399A1 (es) 2013-04-06
BR112012000413A2 (pt) 2020-08-11
BR112012000413B1 (pt) 2022-02-15
CN102471341A (zh) 2012-05-23
US20160108051A1 (en) 2016-04-21
SI2451814T1 (sl) 2014-08-29
AU2010271247B2 (en) 2013-07-18
WO2011006143A2 (en) 2011-01-13
PT2451814E (pt) 2014-07-16
EP2737927A1 (en) 2014-06-04
CU20120002A7 (es) 2012-06-21
HK1164304A1 (en) 2012-09-21
CA2767664A1 (en) 2011-01-13
US8557801B2 (en) 2013-10-15
US20130281403A1 (en) 2013-10-24
US9469645B2 (en) 2016-10-18
JP2012532890A (ja) 2012-12-20
ES2574529T3 (es) 2016-06-20
WO2011006143A3 (en) 2011-06-09
TWI421252B (zh) 2014-01-01
UY32776A (es) 2011-02-28
JO3156B1 (ar) 2017-09-20
MY157238A (en) 2016-05-13
MX2012000389A (es) 2012-03-07
DK2451814T3 (da) 2014-07-14

Similar Documents

Publication Publication Date Title
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201101477A1 (ru) Органические соединения и их применение
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
EA201491505A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201170772A1 (ru) Органические соединения
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201290919A1 (ru) Индазольные соединения и их применение
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
EA201100299A1 (ru) Органические соединения
EA201270590A1 (ru) Ингибиторы акт
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2012002759A (es) Compuestos quimicos.
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201170832A1 (ru) Пуриновые соединения
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201370071A1 (ru) Способы и композиции для лечения рака легких

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PC4A Registration of transfer of a eurasian patent by assignment